JPRN-UMIN000022082
Completed
Phase 1
A phase I study of combination immunotherapy with five peptides cocktail, CpG, and immune modulators for patients with advanced or metastatic colorectal cancer - A phase I study of combination immunotherapy against mCRC
Conditionscolorectal cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- colorectal cancer
- Sponsor
- Yamaguchi University
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Uncontroled general complication. etc
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The phase I study of the combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and tumor-specific peptide pulsed dendritic cells for patients with advanced head and neck mucosal melanomaHead and neck mucosal malignant melanomaJPRN-UMIN000011508Department of Otorynolaryngology, Head and Neck Surgery9
Completed
Not Applicable
A Phase I Trial of Combined immunotherapy with nivolumab and interferon-beta in Patients with advanced melanoma.advanced melanomaJPRN-UMIN000020222Tohoku University Graduate School of Medicine9
Recruiting
Phase 2
Combined sublingual immunotherapy VALERGEN-DP and VALERGEN-BT-Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000240ational Center of Bioproducts (BIOCEN)120
Completed
Phase 1
A phase I study of combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and autologous lymphocyte activated by autologous tumor tissue for patients with head and neck squamous cell carcinoma.JPRN-UMIN000009431Graduate School of Medicine, Chiba University, Department of Otorynolaryngology9
Active, not recruiting
Not Applicable
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2008-001421-34-DEniversity of Cologne, Sponsor-Quality Management16